AMY JANOFSKI: Open Payments
NPI 1427654516 · SHEPHERD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 24 payments from 12 companies in 2025. Trend: 2023 $65 · 2024 $426 · 2025 $609
Food & beverage: $582Education: $28
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $101 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Antares Pharma, Inc. | 4 | $68 |
| Novo Nordisk Inc | 2 | $45 |
| ABBVIE INC. | 2 | $37 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
Products named: AIRSUPRA, EOHILIA, FANAPT, XYOSTED, VRAYLAR, TRELEGY ELLIPTA, CAPLYTA, ZEPBOUND.
Industry payments across MI — which companies pay providers there.
